atai Life Sciences Reports First Quarter 2023 Financial Results and Announces...

COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights

MIND CURE CLOSES PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT

Optimi Health Granted Natural Health Product Site Licence By Health Canada

Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces...

PT409 – Pathology, the DSM, and the Ontological Shock of Psychedelic...

Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic...

Terran Biosciences announces publication of PCT patent application covering novel non-hallucinogenic...

Psychedelic Research Bulletin: April 2023

Delix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001

Load more